Complement Dysregulation in Kidney Diseases: Mechanisms, Biomarkers, and Emerging Targeted Therapies
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27083466 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Patryk Jesiołowski und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Transplantology, Immunology, Nephrology and Internal Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland. Hauptthemen laut MEDLINE: Complement System Proteins, Kidney Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 210 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The complement system is the primary defense mechanism against pathogens, acting through opsonization, the membrane attack complex, and classical, lectin, or alternative pathways. These pathways result in the production of key complement components, including C3a (complement component), C5a, and C3b, which recruit inflammatory cells. Complement dysregulation leads to renal disease through the overproduction of anaphylatoxins or inappropriate formation of the membrane attack complex. The levels of complement components have been shown to be useful as predictive markers in acute kidney injury, especially in conditions of alternative pathway activation, and in diseases of immune complex pathology such as lupus nephritis and IgA nephropathy. Genetic defects in complement regulatory proteins result in diseases such as C3 glomerulopathy or atypical hemolytic uremic syndrome, in which uncontrolled C3 convertase activity results in renal failure. Therapeutic interventions targeting complement components, including eculizumab or pegcetacoplan, improve patient outcomes in atypical hemolytic uremic syndrome and C3 glomerulopathy, respectively, while other interventions improve renal function in IgA nephropathy. These findings underscore the dual role of the complement system, which is not only implicated in the progression of renal diseases but also provides the potential for the development of therapeutic interventions for the treatment of various forms of nephropathy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Transplantology, Immunology, Nephrology and Internal Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland.
- Transplantation and Nephrology Student Scientific Association, Department of Transplantology, Immunology, Nephrology and Internal Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland.
ORCID-Profile: Magdalena Durlik
Zitieren
APA
Jesiołowski, P., Krzywda, M., Furmańczyk-Zawiska, A., & Durlik, M. (2026). Complement Dysregulation in Kidney Diseases: Mechanisms, Biomarkers, and Emerging Targeted Therapies. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27083466
Vancouver
Jesiołowski P, Krzywda M, Furmańczyk-Zawiska A, Durlik M. Complement Dysregulation in Kidney Diseases: Mechanisms, Biomarkers, and Emerging Targeted Therapies. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27083466
BibTeX
@article{Jesioowski2026,
author = {Jesiołowski, Patryk and Krzywda, Mateusz and Furmańczyk-Zawiska, Agnieszka and Durlik, Magdalena},
title = {Complement Dysregulation in Kidney Diseases: Mechanisms, Biomarkers, and Emerging Targeted Therapies},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27083466}
}
EUVIMED